This study was dedicated to investigating the efficacy and safety of the drug Enterosgel® (active substance: polymethylsiloxane polyhydrate) for the treatment of patients with Irritable Bowel Syndrome with Diarrhea predominance (IBS-D).

 Key Results

Subjective Symptoms (GSRS): Patients in the main group treated with Enterosgel® achieved a statistically significant reduction in the severity of complaints on the scales of abdominal pain, diarrheal syndrome, dyspeptic syndrome, as well as on the total score scale.

Clinically Significant Changes: The most clinically significant improvements observed in the Enterosgel® group included normalization of stool frequency (decrease up to 7 times a week), normalization of stool form (up to Bristol Stool Form Scale type 4), and reduction in bodily pain.

Comparison with Control: Unlike the reference drug (bismuth tripotassium dicitrate), Enterosgel® demonstrated a positive effect not only on subjective clinical IBS manifestations but also on the normalization of stool frequency and form.

Motor-Evacuation Function: A tendency towards normalization of GIT motor-evacuation function was noted, although changes in GIT myoelectric activity did not reach statistical significance.

 Conclusion

The study confirmed the safety and efficacy of Enterosgel® in patients with IBS-D. The use of the drug has a positive effect on clinical indicators, reducing abdominal pain and normalizing stool frequency, thereby contributing to the harmonization of quality of life.

The recommended treatment regimen for patients with IBS-D: 22.5 g of paste three times a day one hour after a meal for three consecutive weeks.

Download file: If you would like to see the full data, as well as tables and graphs, please download the file: